Ionis to present at upcoming investor conferences
Get Alerts IONS Hot Sheet
Join SI Premium – FREE
- 2023 Wells Fargo Healthcare Conference on
Wednesday, September 6, 2023 - Citi's 18th Annual BioPharma Conference on
Thursday, September 7, 2023 - Morgan Stanley 21st Annual Global Healthcare Conference on
Tuesday, September 12, 2023
A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.
About Ionis Pharmaceuticals
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-upcoming-investor-conferences-301912983.html
SOURCE Ionis Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ionis Pharmaceuticals (IONS) PT Lowered to $125 at H.C. Wainwright
- A Rare Thing in Dallas: A Paid Federal Civil Rights Fellowship
- STATE ATTORNEYS GENERAL CHALLENGE TO PROPOSED MERGER DEFIES EVIDENCE-BASED ANTITRUST ENFORCEMENT AND MUST BE REJECTED-- DELAY IN CLOSING OF TRANSACTION ONLY BENEFITS BIG TECH AND HARMS CONSUMERS AND H
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Citi, Morgan Stanley, Twitter, Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share